203 related articles for article (PubMed ID: 34757196)
41. Risk factors in the development of esophageal adenocarcinoma.
Pohl H; Wrobel K; Bojarski C; Voderholzer W; Sonnenberg A; Rösch T; Baumgart DC
Am J Gastroenterol; 2013 Feb; 108(2):200-7. PubMed ID: 23247577
[TBL] [Abstract][Full Text] [Related]
42. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
[TBL] [Abstract][Full Text] [Related]
43. Barrett's esophagus: clinical characteristics.
Reynolds JC; Rahimi P; Hirschl D
Gastroenterol Clin North Am; 2002 Jun; 31(2):441-60. PubMed ID: 12134612
[TBL] [Abstract][Full Text] [Related]
44. Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
Avidan B; Sonnenberg A; Schnell TG; Chejfec G; Metz A; Sontag SJ
Am J Gastroenterol; 2002 Aug; 97(8):1930-6. PubMed ID: 12190156
[TBL] [Abstract][Full Text] [Related]
45. Who Deserves Endoscopic Screening for Esophageal Neoplasia?
Blevins CH; Iyer PG
Gastrointest Endosc Clin N Am; 2017 Jul; 27(3):365-378. PubMed ID: 28577762
[TBL] [Abstract][Full Text] [Related]
46. Endoscopy for Barrett's esophagus and esophageal adenocarcinoma.
Shaheen N
Am Fam Physician; 2004 May; 69(9):2060-1. PubMed ID: 15152951
[No Abstract] [Full Text] [Related]
47. Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans.
Rubenstein JH; Sonnenberg A; Davis J; McMahon L; Inadomi JM
Gastrointest Endosc; 2008 Nov; 68(5):849-55. PubMed ID: 18547567
[TBL] [Abstract][Full Text] [Related]
48. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
[TBL] [Abstract][Full Text] [Related]
49. Bacterial Composition of the Human Upper Gastrointestinal Tract Microbiome Is Dynamic and Associated with Genomic Instability in a Barrett's Esophagus Cohort.
Gall A; Fero J; McCoy C; Claywell BC; Sanchez CA; Blount PL; Li X; Vaughan TL; Matsen FA; Reid BJ; Salama NR
PLoS One; 2015; 10(6):e0129055. PubMed ID: 26076489
[TBL] [Abstract][Full Text] [Related]
50. Barrett's Esophagus - State of the Art.
Tanţău M; Laszlo M; Tanţău A
Chirurgia (Bucur); 2018; 113(1):46-60. PubMed ID: 29509531
[TBL] [Abstract][Full Text] [Related]
51. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies.
Rubenstein JH; Scheiman JM; Sadeghi S; Whiteman D; Inadomi JM
Am J Gastroenterol; 2011 Feb; 106(2):254-60. PubMed ID: 21139576
[TBL] [Abstract][Full Text] [Related]
52. Differential response to preoperative chemoradiation and surgery in esophageal adenocarcinomas based on presence of Barrett's esophagus and symptomatic gastroesophageal reflux.
Agarwal B; Swisher SG; Ajani J; Kelly K; Komaki RR; Abu-Hamda E; Correa AM; Roth JA
Ann Thorac Surg; 2005 May; 79(5):1716-23. PubMed ID: 15854962
[TBL] [Abstract][Full Text] [Related]
53. Screening for Barrett's esophagus.
DeVault KR
Am Fam Physician; 2004 May; 69(9):2061-3. PubMed ID: 15152952
[No Abstract] [Full Text] [Related]
54. Barrett's esophagus. Reducing the risk of progression to adenocarcinoma.
Reynolds JC; Waronker M; Pacquing MS; Yassin RR
Gastroenterol Clin North Am; 1999 Dec; 28(4):917-45. PubMed ID: 10695010
[TBL] [Abstract][Full Text] [Related]
55. Reflux disease and Barrett's esophagus.
Qumseya BJ; Wolfsen CL; Wolfsen HC
Endoscopy; 2011 Nov; 43(11):962-5. PubMed ID: 22057759
[No Abstract] [Full Text] [Related]
56. The Epidemiology of Esophageal Adenocarcinoma.
Coleman HG; Xie SH; Lagergren J
Gastroenterology; 2018 Jan; 154(2):390-405. PubMed ID: 28780073
[TBL] [Abstract][Full Text] [Related]
57. Screening and surveillance for complications related to gastroesophageal reflux disease.
Spechler SJ
Am J Med; 2001 Dec; 111 Suppl 8A():130S-136S. PubMed ID: 11749938
[TBL] [Abstract][Full Text] [Related]
58. Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma.
Yen CJ; Izzo JG; Lee DF; Guha S; Wei Y; Wu TT; Chen CT; Kuo HP; Hsu JM; Sun HL; Chou CK; Buttar NS; Wang KK; Huang P; Ajani J; Hung MC
Cancer Res; 2008 Apr; 68(8):2632-40. PubMed ID: 18413730
[TBL] [Abstract][Full Text] [Related]
59. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.
Solaymani-Dodaran M; Logan RF; West J; Card T; Coupland C
Gut; 2004 Aug; 53(8):1070-4. PubMed ID: 15247170
[TBL] [Abstract][Full Text] [Related]
60. Management strategies of Barrett's esophagus.
De Palma GD
World J Gastroenterol; 2012 Nov; 18(43):6216-25. PubMed ID: 23180941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
